洛拉替尼一线治疗间变性淋巴瘤激酶突变阳性
非小细胞肺癌患者的快速卫生技术评估
闫雨婷# , 孙洁雨# , 李 茜
Rapid health technology assessment of lorlatinib in the first-line treatment of
anaplastic lymphoma kinase mutation-positive non-small cell lung cancer
YAN Yuting# , SUN Jieyu# , LI Qian
世界临床药物
.
2024, (3): 317
-323
.
DOI: 10.13683/j.wph.2024.03.013
